Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Update

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 4,190,000 shares, an increase of 345.9% from the February 28th total of 939,600 shares. Approximately 17.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 22,260,000 shares, the short-interest ratio is presently 0.2 days.

Institutional Trading of Syros Pharmaceuticals

A hedge fund recently raised its stake in Syros Pharmaceuticals stock. Exome Asset Management LLC boosted its position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 298,575 shares of the company’s stock after buying an additional 139,400 shares during the quarter. Exome Asset Management LLC owned approximately 1.11% of Syros Pharmaceuticals worth $642,000 as of its most recent filing with the Securities & Exchange Commission. 91.47% of the stock is currently owned by institutional investors.

Syros Pharmaceuticals Stock Down 10.9 %

NASDAQ SYRS opened at $0.03 on Friday. The firm has a market cap of $727,147.20, a price-to-earnings ratio of -0.01 and a beta of 1.31. The company has a 50-day simple moving average of $0.14 and a two-hundred day simple moving average of $0.80. Syros Pharmaceuticals has a 12-month low of $0.02 and a 12-month high of $6.93.

Analyst Ratings Changes

Separately, StockNews.com started coverage on Syros Pharmaceuticals in a research note on Saturday. They issued a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.